Theophylline serum levels unmodified by postprandial administration of a sustained-release preparation (Teonova). 1988

G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
Department of Pneumonology, Unità Sanitaria Locale, Rovigo, Italy.

The authors studied serum theophylline levels after administration of new single-dose capsules: Teonova. Special attention was paid to possible fluctuations of serum theophylline after administration of the drug following a standardized meal. For this purpose a test was carried out on eight male patients with intrinsic asthma. The patients were given a dose able to produce a serum concentration of theophylline of between 10 mcg and 20 mcg at the tenth hour after the administration. This dose was found to be 400 mg (2 tablets of 200 mg) for one patient and 600 mg (2 tablets of 300 mg) for the remaining seven. The capsules of Teonova were administered to each patient for two subsequent days at 07h00. On the first day the patients had their capsules after fasting, and on the second day after a standardized meal. The test proved that Teonova assured a satisfactory serum theophylline level throughout the 24 hours in all patients; food in no way affected the absorption kinetics of the drug. Such features make Teonova suitable for long-term theophylline therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D013806 Theophylline A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP. 1,3-Dimethylxanthine,3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione,Accurbron,Aerobin,Aerolate,Afonilum Retard,Aquaphyllin,Armophylline,Bronchoparat,Bronkodyl,Constant-T,Elixophyllin,Euphylong,Glycine Theophyllinate,Lodrane,Monospan,Nuelin,Nuelin S.A.,Quibron T-SR,Slo-Phyllin,Somophyllin-T,Sustaire,Synophylate,Theo Von Ct,Theo-24,Theo-Dur,Theobid,Theocin,Theoconfin Continuous,Theodur,Theolair,Theolix,Theon,Theonite,Theopek,Theophylline Anhydrous,Theophylline Sodium Glycinate,Theospan,Theostat,Theovent,Uniphyl,Uniphyllin,Uniphylline,1,3 Dimethylxanthine,Anhydrous, Theophylline,Constant T,ConstantT,Ct, Theo Von,Glycinate, Theophylline Sodium,Quibron T SR,Quibron TSR,Slo Phyllin,SloPhyllin,Sodium Glycinate, Theophylline,Somophyllin T,SomophyllinT,Theo 24,Theo Dur,Theo24,Theophyllinate, Glycine,Von Ct, Theo

Related Publications

G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
April 1978, Annals of allergy,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
January 1981, European journal of clinical pharmacology,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
January 1983, European journal of clinical pharmacology,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
January 1983, European journal of clinical pharmacology,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
January 1984, The Journal of asthma : official journal of the Association for the Care of Asthma,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
December 1979, American journal of hospital pharmacy,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
January 1985, Medicina clinica,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
August 1980, Annals of allergy,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
July 1980, Pediatrics,
G F Cannizzaro, and L Pesce, and P Zanoli, and G F Milani, and F Zannoni, and F Pivirotto
March 1977, The Medical journal of Australia,
Copied contents to your clipboard!